Mizuho analyst Christopher Parkinson maintains Mosaic (NYSE:MOS) with a Buy and lowers the price target from $89 to $84.
Analyst Ratings for NGM Biopharmaceuticals
NGM Biopharmaceuticals (NASDAQ:NGM) has observed the following analyst ratings within the last quarter: